Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. Faron Pharmaceuticals Oy
  6. Company
    FARN   FI4000153309

FARON PHARMACEUTICALS OY

(FARN)
  Report
Delayed Quote. Delayed London Stock Exchange - 12/02 05:34:46 am
302.0001 GBX   -2.58%
12/01Faron Pharmaceuticals Appoints Interim Chief Medical Officer
MT
12/01Faron Pharmaceuticals Chief Medical Officer Resigns; Interim Successor Named
MT
12/01Change in Faron's Management Team
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Business Summary
Faron Pharmaceuticals Oy is a Finland-based clinical stage biopharmaceutical company. The CompanyÔÇÖs pipeline is based on endothelial receptors involved in regulation of immune responses and focuses on acute organ traumas, vascular damage and cancer immunotherapy. The Company has two technological platforms: Traumakine and Clevegen. Traumakine aims to prevent vascular leakage and organ failure under ischemic condition. It is undergoing Phase III clinical trials for the treatment of Acute Respiratory Distress Syndrome (ARDS) and European Phase II trial for the prevention of multi-organ failure after emergency aortic surgery for a Rupture of Abdominal Aorta Aneurysm (RAAA). Clevegen is a ground breaking early clinical anti-Clever-1 antibody able to switch immune suppression to immune activation in various conditions, with potential across oncology, infectious disease and vaccine development. It may be used alone or in combination with other immune checkpoint molecules.
Managers
Name Title Age Since
Markku Tapani Jalkanen, Dr. Chief Executive Officer & Executive Director 66 2003
Toni Haenninen Chief Financial Officer - 2019
Matti Karvonen, Dr. Chief Medical Officer & VP-Drug Development - -
Jami Mandelin, Dr. Research Director - 2017
Leopoldo Giampaolo Zambeletti Independent Non-Executive Director 53 2015
Frank Murdoch Armstrong, Dr. Non-Executive Chairman 64 2016
Greg B. Brown, Dr. Independent Non-Executive Director 66 2017
John Poulos Independent Non-Executive Director 66 2017
Yrj÷ Erik Kristian Wichmann Vice President-Finance & Investor - 2019
Juho Markku Jalkanen, Dr. Chief Development Officer 42 -
Members of the board
Name Title Age Since
Frank Murdoch Armstrong, Dr. Non-Executive Chairman 64 2016
Markku Tapani Jalkanen, Dr. Chief Executive Officer & Executive Director 66 2003
Matti Esa Manner Non-Executive Vice Chairman 67 -
Leopoldo Giampaolo Zambeletti Independent Non-Executive Director 53 2015
Greg B. Brown, Dr. Independent Non-Executive Director 66 2017
John Poulos Independent Non-Executive Director 66 2017
Anne Michelle Clem Whitaker Non-Executive Director 52 2021
Equities
Vote QuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 53,232,032 30,057,839 56.5% 0 0.0% 56.5%
Shareholders
NameEquities%
Timo Kalevi Syrjńlń 8,873,402 16.7%
Tom Erik Lind 3,806,611 7.15%
A&B (HK) Co. Ltd. 3,408,409 6.40%
Markku Tapani Jalkanen 3,226,677 6.06%
Marko Salmi 2,673,687 5.02%
Fjńrde AP-fonden 2,632,385 4.95%
Juho Markku Jalkanen 1,089,888 2.05%
Maija-Leena HollmÚn 807,542 1.52%
Rhenman & Partners Asset Management AB 800,000 1.50%
Markku Petteri Kaloniemi 787,266 1.48%
Company contact information
Faron Pharmaceuticals Oy
Joukahaisenkatu 6
Intelligate
Turku, Southwest Finland 20520

Phone : +358.2.469.5151
Fax : +358.2.469.5152
Web : http://www.faron.com
Brand Portfolio
In partnership withAllbrands.markets
More brands of Faron Pharmaceuticals Oy